Troglitazone treatment increases plasma vascular endothelial growth factor in diabetic patients and its mRNA in 3T3-L1 adipocytes

Diabetes
M EmotoY Oka

Abstract

Troglitazone is one of the thiazolidinediones, a new class of oral antidiabetic compounds that are ligands of peroxisome proliferator-activated receptor-gamma. This study on vascular endothelial growth factor (VEGF), also known as vascular permeability factor, was prompted by our clinical observation that the characteristics of troglitazone-induced edema were very similar to those caused by vascular hyperpermeability. When Japanese diabetic patients were screened for plasma VEGF, we found levels to be significantly (P < 0.001) increased in troglitazone-treated subjects (120.1 +/- 135.0 pg/ml, n = 30) compared with those treated with diet alone (29.2 +/- 36.1 pg/ml, n = 10), sulfonylurea (25.8 +/- 22.2 pg/ml, n = 10), or insulin (24.6 +/- 19.0 pg/ml, n = 10). Involvement of troglitazone in increased VEGF levels was further supported by the plasma VEGF levels in five patients before treatment (20.2 +/- 7.0 pg/ml), after 3 months of troglitazone treatment (83.6 +/- 65.9 pg/ml), and 3 months after discontinuation (28.0 +/- 11.6 pg/ml). We further demonstrated that troglitazone, as well as rosiglitazone, at the plasma concentrations observed in patients, increased VEGF mRNA levels in 3T3-L1 adipocytes. VEGF is an angiogenic and mito...Continue Reading

References

Oct 15, 1985·International Journal of Cancer. Journal International Du Cancer·R R LobbJ W Fett
Nov 3, 1994·The New England Journal of Medicine·J J NolanJ Olefsky
Sep 5, 1996·Nature·D ChakravartiR M Evans
May 24, 1997·Lancet·Y TanakaH Yamashita
Nov 21, 1997·Biochemical and Biophysical Research Communications·J Mizukami, T Taniguchi
Jan 23, 1998·BMJ : British Medical Journal·J Wise
Mar 28, 1998·The New England Journal of Medicine·P B Watkins, R W Whitcomb
Mar 10, 1999·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I HyodoY Kotani

❮ Previous
Next ❯

Citations

Dec 18, 2001·Diabetes/metabolism Research and Reviews·B NazlielB Koçer
Jan 16, 2002·Current Hypertension Reports·Nikolaus Marx
May 4, 2013·Drugs·Olga E MakriConstantine D Georgakopoulos
Dec 3, 2005·International Journal of Cardiology·Mouhamad H AbdallahHabib A Dakik
Sep 12, 2002·Trends in Molecular Medicine·Caroline DuvalBart Staels
May 5, 2006·Nature Reviews. Drug Discovery·Vera Regitz-Zagrosek
Oct 25, 2002·Diabetes Technology & Therapeutics·Fei WangCunegundo M Vergara
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Sunil AsnaniVivian A Fonseca
May 25, 2010·Cardiovascular Research·Virginia H Huxley, Jianjie Wang
Jun 14, 2006·Retina·Edwin H RyanDavid F Williams
Aug 31, 2011·Anti-cancer Drugs·Ingrid M E DesarWinette T A van der Graaf
Aug 17, 2006·Journal of Gastroenterology and Hepatology·Andreas SchäfflerHans Herfarth
Jun 16, 2010·Respirology : Official Journal of the Asian Pacific Society of Respirology·Eun Kyung KimSang-Do Lee
Feb 24, 2011·American Journal of Physiology. Endocrinology and Metabolism·Qing HeJianping Ye
May 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shira Landskroner-EigerPhilipp E Scherer
Sep 4, 2012·BMC Ophthalmology·Maxwell P Treacy, Tara P Hurst
Jan 23, 2009·Journal of the American Society of Nephrology : JASN·Volker VallonJames Stockand
Jan 1, 2009·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Giuseppe Derosa, Sibilla At Salvadeo
Apr 22, 2010·Vascular Health and Risk Management·Toshikazu Yamanouchi
Nov 7, 2006·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·David P Macfarlane, Miles Fisher
Nov 11, 2003·Current Medical Research and Opinion·Sunil AsnaniVivian Fonseca
Jul 20, 2010·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Domenico MeranteFrancesco M Bandello
Sep 16, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·André J Scheen
Jun 13, 2009·Best Practice & Research. Clinical Endocrinology & Metabolism·Kaivan KhavandiRayaz A Malik
Feb 3, 2009·American Journal of Ophthalmology·Donald S Fong, Richard Contreras
Jan 28, 2009·Survey of Ophthalmology·Neelakshi BhagatMarco A Zarbin
Aug 19, 2007·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Po-Hsun HuangRyozo Nagai
May 4, 2004·Journal of Diabetes and Its Complications·Paresh Dandona, Ahmad Aljada
Jul 5, 2005·Biochemical and Biophysical Research Communications·Baichun YangGreg L Pahel
Dec 18, 2003·The American Journal of Medicine·Vivian Fonseca
Jan 5, 2005·The American Journal of Medicine·Maulik ShahWilliam F Fearon
Apr 20, 2004·European Journal of Pharmacology·Harold E Lebovitz, Mary Ann Banerji
May 4, 2005·Journal of Diabetes and Its Complications·Giancarlo Viberti
Feb 23, 2013·PPAR Research·Andreea CiudinRafael Simó
Jul 7, 2015·Journal of Ophthalmology·Su ZhangNan Hu
Oct 30, 2003·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Sunder MudaliarRobert R Henry
Feb 24, 2015·Molecular and Cellular Endocrinology·Arif U HasanMasakazu Kohno

❮ Previous
Next ❯

Related Concepts

Related Feeds

American Diabetes Association Journals

Discover the latest diabetes research published by the journals from the American Diabetes Association.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Related Papers

Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
Hassan T RahmanChris S Bergstrom
Ophthalmic Surgery, Lasers & Imaging : the Official Journal of the International Society for Imaging in the Eye
Vassilios PanteleontidisMiltiadis K Tsilimbaris
© 2021 Meta ULC. All rights reserved